Description and references

Semi-synthetic macrolide antibiotic; related to erythromycin A, q.v. Prepn: BE 892357; G. Kobrehel, S. Djokic, US 4517359 (1982, 1985 both to Sour Pliva); of the crystalline dihydrate: D. J. M. Allen, K. M. Nepveux, EP 298650; eidem, US 6268489 (1989, 2001 both to Pfizer). Antibacterial spectrum: S. C. Aronoff et al., J. Antimicrob. Chemother. 19, 275 (1987); and mode of action: J. Retsema et al., Antimicrob. Agents Chemother. 31, 1939 (1987). LC-MS determin in plasma: B.-M. Chen et al., J. Pharm. Biomed. Anal. 42, 480 (2006). Series of articles on pharmacology, pharmacokinetics, and clinical experience: J. Antimicrob. Chemother. 31, Suppl. E, 1-198 (1993). Clinical trial in prevention of Pneumocystis carinii pneumonia in AIDS patients: M. W. Dunne et al., Lancet 354, 891 (1999); in cystic fibrosis: A. Clement et al., Thorax 61, 895 (2006); in P. vivax malaria: M. W. Dunne et al., Am. J. Trop. Med. Hyg. 73, 1108 (2005). Review of pharmacology and clinical efficacy in pediatric infections: H. D. Langtry, J. A. Balfour, Drugs 56, 273-297 (1998). Review of clinical evaluation in lower respiratory tract infections: F. Blasi et al., Expert Opin. Pharmacother. 6, 2335-2351 (2005).

Properties

Derivative